Citation and commencement

1.  These Regulations may be cited as the Misuse of Drugs (Amendment No.2) Regulations (Northern Ireland) 2010 and shall come into operation on 23rd July 2010.

Interpretation

2.—(1) In these Regulations, “the 2002 Regulations” means the Misuse of Drugs Regulations (Northern Ireland) 2002(3).

(2) The Interpretation Act (Northern Ireland) 1954(4) shall apply to these Regulations as it applies to an Act of the Assembly.

Amendment to the 2002 Regulations

3.  The 2002 Regulations shall be amended as follows.

4.  In Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27) after paragraph 1(m), insert—

“(n)Any compound structurally derived from 2-aminopropan-1–one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say—

(i)by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(ii)by substitution at the 3–position with an alkyl substituent;

(iii)by substitution at the 2‑amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2‑amino nitrogen atom in a cyclic structure.”.

EXPLANATORY NOTE

(This note is not part of the Regulations)

These Regulations insert a further group of cathinone derivatives (including naphthylpyrovalerone, commonly known as naphyrone) into Schedule 1 to the Misuse of Drugs Regulations (Northern Ireland) 2002. The schedule in which a controlled drug is placed primarily affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to that drug.